Occlutech International AB
Location
Skåne
Founded
2007-01-23
Website
Risk Signals
43 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Equipment, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Occlutech International AB
Live alerts from global media, monitored by Business Radar
(dicardiology.com)
Occlutech's Atrial Flow Regulator for Heart Failure Receives FDA Breakthrough Device Designation |
January, 27, 2021 — The U.S. Food and Drug Administration (FDA) has granted Occlutech a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator (AFR) for heart failure (HF) patients with preserved (HFpEF) or reduced (HFrEF) ejection fraction. The AFR is used in patients who, despite optimal medical therapy, experience worsening symptoms. The AFR maintains an interatrial shunt with a predetermined diameter allowing for controlled blood flow from the left to the right atrium enabling the left atrium to decompress and lower left atrial pressure. Reduced left atrial pressure has been shown to reduce heart failure symptoms and improve exercise tolerance. Breakthrough Device Designations aim to accelerate the development, assessment, and approval of new treatments in severe diseases, including a prioritized review all the way through market approval. "It is an important milestone for us to have received this second breakthrough designation for our AFR device." said Sabine Bois, CEO
Read more